Upon joining the study, you will be informed about the purpose and procedures involved. This study is an open-label extension, meaning you will know the medication you are receiving.

You will be required to have completed a previous study with an acceptable safety profile, as judged by the investigator.

You will receive the medication called olezarsen, also known as ISIS 678354. This medication is administered through an injection under the skin, known as a subcutaneous injection.

The dosage and frequency of the medication will be determined by the study protocol and your healthcare provider.

You will continue to receive the medication as part of your treatment for severe hypertriglyceridemia (SHTG). This condition involves high levels of triglycerides in the blood.

Your treatment will be part of a stable regimen of lipid-lowering therapy, which should follow the standard of care according to local guidelines.

Throughout the study, your health will be closely monitored. This includes regular assessments of your clinical laboratory values, such as platelet count and kidney function.

You will be observed for any adverse events, which are any unwanted effects you might experience during the study.

The study is expected to last up to 66 weeks, with the primary endpoint being the change in clinical laboratory values from baseline to week 53.

Upon completion, you will have a final assessment to evaluate the overall safety and tolerability of the medication.